Published in Malar J on March 18, 2015
Chemoprotective Activity of MMV390048 in PfSPZ Challenge Model | NCT03195387
The March Toward Malaria Vaccines. Am J Prev Med (2015) 0.96
Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines. Vaccine (2015) 0.95
The march toward malaria vaccines. Vaccine (2015) 0.95
Safety, Immunogenicity, and Protective Efficacy of Intradermal Immunization with Aseptic, Purified, Cryopreserved Plasmodium falciparum Sporozoites in Volunteers Under Chloroquine Prophylaxis: A Randomized Controlled Trial. Am J Trop Med Hyg (2015) 0.91
Optimizing Intradermal Administration of Cryopreserved Plasmodium falciparum Sporozoites in Controlled Human Malaria Infection. Am J Trop Med Hyg (2015) 0.82
Robust, reproducible, industrialized, standard membrane feeding assay for assessing the transmission blocking activity of vaccines and drugs against Plasmodium falciparum. Malar J (2015) 0.82
Large screen approaches to identify novel malaria vaccine candidates. Vaccine (2015) 0.80
Alterations of blood coagulation in controlled human malaria infection. Malar J (2016) 0.76
Sporozoite Route of Infection Influences In Vitro var Gene Transcription of Plasmodium falciparum Parasites From Controlled Human Infections. J Infect Dis (2016) 0.76
Plasmodium vivax Controlled Human Malaria Infection - Progress and Prospects. Trends Parasitol (2016) 0.76
In Vitro Variant Surface Antigen Expression in Plasmodium falciparum Parasites from a Semi-Immune Individual Is Not Correlated with Var Gene Transcription. PLoS One (2016) 0.76
DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection. Lancet Infect Dis (2017) 0.75
Mosquito bite immunization with radiation-attenuated Plasmodium falciparum sporozoites: safety, tolerability, protective efficacy and humoral immunogenicity. Malar J (2016) 0.75
Life-span of in vitro differentiated Plasmodium falciparum gametocytes. Malar J (2017) 0.75
Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei. Nature (1967) 6.08
Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet (2008) 5.49
Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis (2002) 5.43
Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity. Science (2011) 4.72
Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science (2013) 4.60
Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci (1973) 4.18
Protection against a malaria challenge by sporozoite inoculation. N Engl J Med (2009) 4.03
Detection of Plasmodium falciparum malaria parasites in vivo by real-time quantitative PCR. Mol Biochem Parasitol (2001) 3.49
Comparison of methods for the rapid laboratory assessment of children with malaria. Am J Trop Med Hyg (2001) 3.44
Intravital microscopy demonstrating antibody-mediated immobilisation of Plasmodium berghei sporozoites injected into skin by mosquitoes. Int J Parasitol (2004) 2.78
Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol (2011) 2.53
Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin (2010) 2.36
Letter: Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans R Soc Trop Med Hyg (1974) 2.22
Clinical outcome of experimental human malaria induced by Plasmodium falciparum-infected mosquitoes. Neth J Med (2005) 2.10
Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. J Infect Dis (2007) 1.94
Plasmodium falciparum-infected Anopheles stephensi inconsistently transmit malaria to humans. Am J Trop Med Hyg (1990) 1.85
Comparison of clinical and parasitological data from controlled human malaria infection trials. PLoS One (2012) 1.64
Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg (2012) 1.62
Estimation of risk due to low doses of microorganisms: a comparison of alternative methodologies. Am J Epidemiol (1983) 1.57
Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc Natl Acad Sci U S A (2013) 1.57
Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe. PLoS One (2013) 1.33
Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg (2014) 1.32
Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trial. PLoS One (2010) 1.14
Visualizing non infectious and infectious Anopheles gambiae blood feedings in naive and saliva-immunized mice. PLoS One (2012) 1.13
Antibodies against PfEMP1, RIFIN, MSP3 and GLURP are acquired during controlled Plasmodium falciparum malaria infections in naïve volunteers. PLoS One (2011) 1.08
Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. Front Microbiol (2014) 1.05
Malarial parasites vs. antimalarials: never-ending rumble in the jungle. Curr Mol Med (2006) 0.99
Successful human infection with P. falciparum using three aseptic Anopheles stephensi mosquitoes: a new model for controlled human malaria infection. PLoS One (2013) 0.95
Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA. Hum Vaccin Immunother (2012) 0.95
The skin: where malaria infection and the host immune response begin. Semin Immunopathol (2012) 0.95
Guidelines for collection, analysis and presentation of vaccine safety data in surveillance systems. Vaccine (2008) 0.86
Chemotherapeutic suppression and prophylaxis in malaria. Trans R Soc Trop Med Hyg (1945) 0.85